ANZBMS e News 18 July 2016
ANZBMS e News 7 July 2016
ANZBMS e News 23 May 2016
ANZBMS e News 3 May 2016
ANZBMS e News 5 February 2016
ANZBMS e News 23 October 2015
ANZBMS e News 28 September 2015
ANZBMS e News 22 September 2015
ANZBMS e News 10 September 2015
ANZBMS e News 24 July 2015
ANZBMS e News 18 June 2015
ANZBMS e News 9 June 2015
ANZBMS e News 28 May 2015
ANZBMS e News 1 May 2015
ANZBMS e News 9 April 2015
ANZBMS e News 27 March 2015
ANZBMS e News 26th February
ANZBMS e News 17 February 2015
ANZBMS e News 15 January 2015
First National Forum on Secondary Fracture Prevention
On 20th November 2015, representatives from 22 organisations gathered in Sydney to
attend the inaugural National Forum on Secondary Fracture Prevention.
This meeting was a direct result of a position Paper Published by the Australia & New
Zealand Bone and Mineral Society (ANZBMS) and endorsed by a large number of
organisations and key stakeholders. The Paper drew attention to the appalling lack
of effective osteoporosis care in Australia, and the shocking fact that 80% of patients
who suffer a fragility fracture receive no treatment to prevent further fractures.
The case for addressing the lack of osteoporosis awareness, both among health
professionals and patients, has been made repeatedly over the past 15 years. However,
despite several ‘white papers’ published in 2001, 2007 and 2013, and even the
inclusion of osteoporosis as part of the 7th Australian National Health Priority1 in 2002,
little or no progress has been made. One reason for this failure was the lack of a
peak body that encompassed ALL stakeholders to speak with one unified voice.
The First National Forum on Secondary Fracture Prevention is a loud and clear call to
action. The aim is to enable all stakeholders to develop a shared understanding of
the key elements of a national approach to secondary fracture prevention, and to
forge a National Alliance to ensure strong advocacy for the uptake of this approach
by Federal and State Governments. Similar Alliances have been formed overseas,
and particularly in the US, and these Alliances have been extremely successful in
getting heard by Governments that would not otherwise have listened.
It is my sincere hope that this forum will mark the first meeting of a successful
National Alliance that will go forward and conquer the unnecessary burden of
secondary fragility fractures on the ageing population of Australia. In the pages of
this report I hope you find the evidence to convince you to take action.
Professor Markus Seibel
University of Western Australia – Scholarship
Arthritis and Osteoporosis WA will fund this scholarship to be awarded under the supervision of Professor Johannes Nossent to the most outstanding PhD candidate, preferably medically trained with a special interest in rheumatology; or a candidate with a solid background in medical science/public health at a Masters level with a special interest in rheumatology. The initial PhD research area will focus on epidemiology of rheumatoid arthritis in WA with a view to expand the research area in the future.
Applications close: 31 March 2016
Massive Parallel Sequencing for Brittle Bone Disorders and Hereditary Rickets
The Children’s Hospital at Westmead has recently developed Massive Parallel Sequencing (MPS) for Brittle Bone Disorders (osteogenesis imperfecta) and Hereditary Rickets.
From one DNA sample, MPS enables mutation testing of 13 genes associated with Brittle Bone Disorders or 9 genes associated with Hereditary Rickets.
Attached is the information sheet, request form and consent form for MPS. Before genetic testing will be undertaken, a completed MPS request form and consent form are required.
If you have any questions please contact the Molecular Genetics Laboratory at CHW. Email: email@example.com Phone: [61-2]9845 3244 Fax: [61-2]9845 3204.
MINUTES OF A MEETING OF THE BOARD OF DIRECTORS OF THE AUSTRALIAN SOCIETY FOR MEDICAL RESEARCH (ASMR) AND REPRESENTATIVES OF AFFILIATE MEMBER SOCIETIES AND MEDICAL COLLEGES HELD AT THE VIBE HOTEL RUSHCUTTERS BAY, COMMENCING AT 4:45PM ON MARCH 24, 2015
ANZBMS 2015 AGM
ANZBMS 2016 AGM
RACP Selection into Training Draft Policy Consultation Pack
Dear ANZBMS member,
The Royal Australasian College of Physicians is consulting on a ‘Selection into Training’ policy and has identified ANZBMS as a key stakeholder in this process. The RACP would like to invite ANZBMS to provide feedback on the draft ‘Selection into Training’ policy.
Attached are a cover letter and an associated consultation pack relating to the draft policy.
Musculoskeletal conditions are the leading contributors to disability burden globally and account for 27.4 per cent of total disability burden in Australia.
Arthritis and other musculoskeletal conditions cost Australia $55.1 billion annually but only $4 million is spent on clinical trials, a new report shows.
A new report into the scope of musculoskeletal (MSK) clinical trials in Australia has revealed that, relative to the burden of arthritis and other MSK conditions on the Australian community, national funding for research is disproportionately low.
The report, led by Professor Rachelle Buchbinder, from the Department of Epidemiology and Preventive Medicine and the Cabrini Institute, shows that despite arthritis and MSK conditions affecting 6.1 million people (26.9 per cent of the Australian population), research is severely underfunded.
Funded by Arthritis and Osteoporosis Victoria (A&OV), The scope, funding and publication of musculoskeletal clinical trials performed in Australia (2009 - 2013) report published in the Medical Journal of Australia, found that despite the rising cost of MSK conditions in Australia - $55.1 billion in 2012 – only $4 million was spent on clinical trials in the same year.
The findings suggest an urgent need for greater investment to provide relief to the 6.1 million Australians who live in pain from MSK conditions.
Professor Buchbinder noted that the $55.1 billion cost to the Australian community is projected to rise as the population ages.
“Timely research that addresses important questions relevant to consumers, clinicians and policymakers and reduces the sizeable delays in translating evidence into practice is critical for reducing the burden associated with these conditions,” Professor Buchbinder said.
In the last five years, the National Health and Medical Research Council (NHMRC) has awarded 29 project grants (and over $17.6 million) in support of Australian MSK trials. While this may seem a lot, it actually works out to be 0.8 per cent of the total NHMRC grants (29 out of 3631 or $17.6 million out of $354 million).
A&OV is the peak body representing Victorians living with arthritis and over 100 other MSK conditions.
Osteoporosis Australia launched a new Burden of Disease study on 4 December titled, Osteoporosis Costing All Australians – A new Burden of Disease analysis 2012-2022.
The report clearly demonstrates the significant impact osteoporosis, and related fractures, have on the current healthcare system and estimates for the next decade indicate costs of over $33 billion.
The event hosted at Parliament House in Canberra was attend